RadNet (NASDAQ:RDNT) Upgraded by Zacks Research to “Hold” Rating

Posted by Brian Himes on Aug 15th, 2026

Zacks Research upgraded shares of RadNet (NASDAQ:RDNT – Free Report) from a strong sell rating to a hold rating in a research note published on Thursday,Zacks.com reports.

Several other equities analysts have also commented on RDNT. Barclays reduced their price objective on RadNet from $70.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a research report on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating on shares of RadNet in a research report on Friday, July 31st. Finally, Truist Financial increased their price target on shares of RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $88.00.

Read Our Latest Stock Analysis on RadNet

RadNet Stock Down 1.2%

RDNT opened at $76.35 on Thursday. The stock has a market cap of $6.01 billion, a PE ratio of -282.77 and a beta of 1.36. The company has a quick ratio of 1.17, a current ratio of 1.48 and a debt-to-equity ratio of 0.94. RadNet has a 52 week low of $50.82 and a 52 week high of $85.84. The business’s fifty day simple moving average is $63.31 and its 200 day simple moving average is $61.90.

RadNet (NASDAQ:RDNT – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The medical research company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.09. RadNet had a positive return on equity of 2.61% and a negative net margin of 0.93%.The business had revenue of $622.72 million for the quarter, compared to the consensus estimate of $610.87 million. During the same quarter last year, the business posted $0.31 earnings per share. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. As a group, research analysts expect that RadNet will post 0.49 earnings per share for the current fiscal year.

Insider Activity

In other RadNet news, CEO Cornelis Wesdorp sold 4,750 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total transaction of $276,022.50. Following the completion of the sale, the chief executive officer directly owned 69,075 shares in the company, valued at $4,013,948.25. This represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David L. Swartz sold 2,699 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $53.89, for a total value of $145,449.11. Following the transaction, the director directly owned 177,013 shares in the company, valued at $9,539,230.57. This trade represents a 1.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 5.14% of the company’s stock.

Hedge Funds Weigh In On RadNet

Several institutional investors and hedge funds have recently bought and sold shares of RDNT. Geneos Wealth Management Inc. bought a new stake in RadNet in the fourth quarter valued at approximately $25,000. Allworth Financial LP boosted its stake in shares of RadNet by 346.6% during the third quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 305 shares during the period. Danske Bank A S bought a new position in shares of RadNet in the third quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. bought a new position in shares of RadNet in the fourth quarter worth approximately $36,000. Finally, Harbour Investments Inc. purchased a new position in shares of RadNet in the fourth quarter worth $42,000. 77.90% of the stock is currently owned by institutional investors.

RadNet Company Profile

(Get Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.